Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETONNASDAQ:SBBPNASDAQ:SBTXNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$17.25+1.8%$16.08$3.18▼$21.48$462.61M1.22306,103 shs403,842 shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsSBTXSilverback Therapeutics$14.53+0.5%$13.88$2.80▼$8.97$523.92M0.6337,931 shs1.16 million shsUPBUpstream Bio$10.85-0.1%$8.41$5.14▼$29.46$583.83MN/A333,783 shs173,111 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals-1.91%-15.59%-0.12%+17.46%+370.83%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%SBTXSilverback Therapeutics+0.48%-0.62%+0.48%+33.67%+62.53%UPBUpstream Bio+0.18%+17.79%+25.12%+28.98%+1,085,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETONEton Pharmaceuticals3.164 of 5 stars3.55.00.00.03.40.80.6SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPBUpstream Bio1.9912 of 5 stars3.50.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 3.00Buy$29.6771.98% UpsideSBBPStrongbridge Biopharma 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/AUPBUpstream Bio 3.00Buy$56.50420.59% UpsideCurrent Analyst Ratings BreakdownLatest SBBP, SBTX, ETON, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.003/19/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.003/19/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $24.003/19/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$48.33M9.57$0.00 per share4,502.79$0.60 per share28.75SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AUPBUpstream Bio$2.30M254.28N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$940K-$0.18N/A34.50N/A-15.81%-36.29%-16.84%8/14/2025 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/AUPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)Latest SBBP, SBTX, ETON, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million3/18/2025Q4 2024ETONEton Pharmaceuticals-$0.02-$0.02N/A-$0.02$10.53 million$11.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton PharmaceuticalsN/A1.511.41SBBPStrongbridge Biopharma0.383.002.95SBTXSilverback TherapeuticsN/A67.8767.87UPBUpstream BioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%SBBPStrongbridge Biopharma52.03%SBTXSilverback Therapeutics74.89%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.03%SBBPStrongbridge Biopharma5.10%SBTXSilverback Therapeutics34.40%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2026.82 million22.17 millionOptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableUPBUpstream Bio3853.79 millionN/AN/ASBBP, SBTX, ETON, and UPB HeadlinesRecent News About These CompaniesUpstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025June 5 at 7:57 AM | quiverquant.comUpstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025June 5 at 7:00 AM | globenewswire.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?June 4 at 4:30 PM | marketbeat.comUpstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4 at 7:00 AM | globenewswire.comUpstream Bio (NASDAQ:UPB) Trading 10.2% Higher - Here's What HappenedJune 3 at 2:45 PM | marketbeat.com1,583,154 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Wellington Management Group LLPJune 1, 2025 | marketbeat.comJane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)May 27, 2025 | marketbeat.comNorthern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)May 27, 2025 | marketbeat.comWoodline Partners LP Buys New Stake in Upstream Bio, Inc. (NASDAQ:UPB)May 25, 2025 | marketbeat.comVR Adviser LLC Takes $37.74 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)May 22, 2025 | marketbeat.comUpstream Bio names new chief technology officerMay 21, 2025 | investing.comUpstream Bio Appoints Stacy Price As CTOMay 21, 2025 | nasdaq.comUpstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical OperationsMay 21, 2025 | nasdaq.comUpstream Bio Appoints Stacy Price as Chief Technology OfficerMay 20, 2025 | globenewswire.comOrbimed Advisors LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)May 15, 2025 | marketbeat.comBalyasny Asset Management L.P. Invests $4.95 Million in Upstream Bio, Inc. (NASDAQ:UPB)May 13, 2025 | marketbeat.comEnavate Sciences GP LLC Acquires Shares of 2,459,703 Upstream Bio, Inc. (NASDAQ:UPB)May 11, 2025 | marketbeat.comQ2 EPS Estimates for Upstream Bio Decreased by William BlairMay 10, 2025 | marketbeat.comDeep Track Capital LP Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)May 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Invests $1.40 Million in Upstream Bio, Inc. (NASDAQ:UPB)May 9, 2025 | marketbeat.comUpstream Bio Advances Verekitug in Clinical TrialsMay 7, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBBP, SBTX, ETON, and UPB Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$17.25 +0.30 (+1.77%) Closing price 04:00 PM EasternExtended Trading$17.16 -0.09 (-0.49%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Silverback Therapeutics NASDAQ:SBTX$14.53 +0.07 (+0.48%) As of 06/3/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Upstream Bio NASDAQ:UPB$10.85 -0.01 (-0.06%) Closing price 03:59 PM EasternExtended Trading$10.81 -0.04 (-0.40%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
